ClinVar Miner

Submissions for variant NM_000520.6(HEXA):c.1073+1G>A (rs76173977)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 13
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
EGL Genetic Diagnostics, Eurofins Clinical Diagnostics RCV000079047 SCV000110916 pathogenic not provided 2012-11-08 criteria provided, single submitter clinical testing
Baylor Genetics RCV000004126 SCV000245491 pathogenic Tay-Sachs disease 2015-07-30 criteria provided, single submitter clinical testing This variant has been previously reported as disease-causing and was found twice in our laboratory in trans with another pathogenic variant: in a 25-year-old female [with c.820-7G>A] with motor delay, hypotonia, scoliosis, progressive weakness, mild ankle contractures, mildly diminished sensation, gait abnormalities, sister possibly similarly symptomatic (not tested); in a 1-year-old male [with Y427fs] with IUGR, severe delays with regression, hypotonia, epilepsy, microcephaly, FTT, polymicrogyria, absent HEXA activity. Variant pathogenic in recessive state; heterozygotes are carriers.
Invitae RCV000004126 SCV000260622 pathogenic Tay-Sachs disease 2020-10-23 criteria provided, single submitter clinical testing This sequence change affects a donor splice site in intron 9 of the HEXA gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. This variant is present in population databases (rs76173977, ExAC 0.04%). This is a common variant in Tay-Sachs disease patients of Western European origin (PMID: 8490625, 1387685, 19858779). ClinVar contains an entry for this variant (Variation ID: 3920). Experimental studies have shown that this variant interferes with normal RNA splicing (PMID: 8444467, 1301938). Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in HEXA are known to be pathogenic (PMID: 1833974, 8490625). For these reasons, this variant has been classified as Pathogenic.
GeneDx RCV000079047 SCV000329361 pathogenic not provided 2018-07-20 criteria provided, single submitter clinical testing The c.1073+1 G>A splice site variant in the HEXA gene has been previously reported in association with Tay-Sachs disease (Akli et al., 1991; Akli et al., 1993). This splice site variant destroys the canonical splice donor site in intron 9, and activates a cryptic donor site 17 base pairs downstream, which leads to a shift in the reading frame and a premature Stop codon (Akli et al., 1993). In summary, we interpret c.1073+1 G>A to be a pathogenic variant.
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology RCV000004126 SCV000584095 pathogenic Tay-Sachs disease 2014-04-10 criteria provided, single submitter research
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000004126 SCV000697161 pathogenic Tay-Sachs disease 2016-11-14 criteria provided, single submitter clinical testing Variant summary: The HEXA c.1073+1G>A variant involves the alteration of a highly conserved nucleotide in the canonical splice donor site in intron 9. This variant was found in 27/119996 control chromosomes, predominantly observed in the European (Non-Finnish) subpopulation at a frequency of 0.0003776 (25/66208). This frequency is about lower the estimated maximal expected allele frequency of a pathogenic HEXA variant (0.0013975). This variant is a known common pathogenic variant mainly found in non-Jewish Caucasian (Landels_1992, Landels_1993, McDowell_1992, Akli_1993, Gort_2012, Utz_2015) with consistent genotype-phenotype and functional data. The frequency in control population therefore represents the carrier frequency. Multiple clinical diagnostic laboratories/reputable databases have classified this variant as pathogenic. Taken together, this variant is classified as Pathogenic.
Fulgent Genetics,Fulgent Genetics RCV000004126 SCV000894057 pathogenic Tay-Sachs disease 2018-10-31 criteria provided, single submitter clinical testing
Myriad Women's Health, Inc. RCV000004126 SCV001194215 pathogenic Tay-Sachs disease 2019-11-12 criteria provided, single submitter clinical testing NM_000520.4(HEXA):c.1073+1G>A(aka IVS9+1G>A) is classified as pathogenic in the context of hexosaminidase A deficiency. Please note that the c.1073+1G>A variant is associated with Tay-Sachs disease. Sources cited for classification include the following: PMID 8444467, 1387685, 22789865, 17015493, 8490625, 1837283 and 1301938. Classification of NM_000520.4(HEXA):c.1073+1G>A(aka IVS9+1G>A) is based on the following criteria: The variant is located at a canonical splice site, is expected to disrupt gene function and is reported in individuals with the relevant phenotype. Please note: this variant was assessed in the context of healthy population screening.
CeGaT Praxis fuer Humangenetik Tuebingen RCV000079047 SCV001249187 pathogenic not provided 2018-09-01 criteria provided, single submitter clinical testing
Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen RCV000079047 SCV001447185 likely pathogenic not provided 2020-10-23 criteria provided, single submitter clinical testing
Illumina Clinical Services Laboratory,Illumina RCV000004126 SCV001451639 pathogenic Tay-Sachs disease 2018-08-22 criteria provided, single submitter clinical testing The HEXA c.1073+1G>A variant occurs in a canonical splice site (donor) and is therefore predicted to disrupt or distort the normal gene product. The c.1073+1G>A variant affects a splice donor site in intron 9 and has been primarily reported in non-Ashkenazi Jewish probands of European descent (Park et al. 2010). Across a selection of available literature, the c.1073+1G>A variant has been identified in a homozygous state in three probands, in a compound heterozygous state in eight probands, in a heterozygous state in five probands in whom a second variant was not identified, and in seven probands in whom zygosity is unknown (Landels et al. 1992; McDowell et al. 1992; Akli et al. 1992; Akerman et al. 1992; Landels et al. 1993; Gort et al. 2012). The c.1073+1G>A variant was also identified in a heterozygous state in 25 unaffected carriers. The c.1073+1G>A variant was absent from 56 control alleles and is reported at a frequency of 0.000388 in the European (non-Finnish) population of the Genome Aggregation Database. RT-PCR analysis demonstrated that the c.1073+1G>A variant disrupts splicing of the HEXA gene and results in the production of numerous abnormal mRNA products (Akerman et al. 1992). Based on the evidence, the c.1073+1G>A variant is classified as pathogenic for hexoaminidase A deficiency.
OMIM RCV000004126 SCV000024292 pathogenic Tay-Sachs disease 1993-06-01 no assertion criteria provided literature only
Foundation for Research in Genetics and Endocrinology, FRIGE's Institute of Human Genetics RCV000004126 SCV000494220 pathogenic Tay-Sachs disease 2014-06-17 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.